MedTrace Logo

PSIL201 Long-term Follow-up Study: Psilocybin or Niacin / Major Depressive Disorder

NCT04353921 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 26

Last updated 2026-05-04

No results posted yet for this study

Summary

This is a Phase 2 double-blind, long-term observational follow-up study of participants from Study PSIL201. Participants providing informed consent were enrolled into this study and completed web surveys and telephone interviews conducted by one central site at the following time intervals: months 3 and 6 (± 7 days for each assessment) and months 10 and 12 (± 14 days for each assessment).

Conditions

Interventions

OTHER

No intervention will be administered as part of this study.

No intervention will be administered as part of this study.

Sponsors & Collaborators

  • Usona Institute

    lead OTHER

Principal Investigators

  • Charles Raison, MD · Usona Institute

Eligibility

Min Age
21 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-30
Primary Completion
2022-10-18
Completion
2022-10-18

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04353921 on ClinicalTrials.gov